What is a stock summary page? Click here for an overview.
Business Description
Blueprint Medicines Corp
NAICS : 325412
SIC : 2834
ISIN : US09627Y1091
Description
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.31 | |||||
| Equity-to-Asset | 0.25 | |||||
| Debt-to-Equity | 1.57 | |||||
| Debt-to-EBITDA | 24.39 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 2.02 | |||||
| Beneish M-Score | -1.32 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 38 | |||||
| 3-Year EPS without NRI Growth Rate | 33.4 | |||||
| 3-Year FCF Growth Rate | 31 | |||||
| 3-Year Book Growth Rate | -34.1 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 33.63 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.51 | |||||
| 9-Day RSI | 45.78 | |||||
| 14-Day RSI | 45.15 | |||||
| 3-1 Month Momentum % | 1.14 | |||||
| 6-1 Month Momentum % | -2.3 | |||||
| 12-1 Month Momentum % | -4.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.85 | |||||
| Quick Ratio | 2.8 | |||||
| Cash Ratio | 2.36 | |||||
| Days Inventory | 337.04 | |||||
| Days Sales Outstanding | 47.28 | |||||
| Days Payable | 94.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.5 | |||||
| Shareholder Yield % | -3.44 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 96.04 | |||||
| Operating Margin % | -41.67 | |||||
| Net Margin % | -13.19 | |||||
| FCF Margin % | -38.76 | |||||
| ROE % | -24.43 | |||||
| ROA % | -5.92 | |||||
| ROIC % | -44.45 | |||||
| 3-Year ROIIC % | -371.73 | |||||
| ROC (Joel Greenblatt) % | 2.71 | |||||
| ROCE % | 0.33 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 11.18 | |||||
| PB Ratio | 19.13 | |||||
| Price-to-Tangible-Book | 19.13 | |||||
| EV-to-EBIT | 1919.56 | |||||
| EV-to-Forward-EBIT | -110.54 | |||||
| EV-to-EBITDA | 293.8 | |||||
| EV-to-Forward-EBITDA | -128.77 | |||||
| EV-to-Revenue | 11.11 | |||||
| EV-to-Forward-Revenue | 7.76 | |||||
| EV-to-FCF | -28.65 | |||||
| Price-to-GF-Value | 0.63 | |||||
| Price-to-Median-PS-Value | 0.3 | |||||
| Earnings Yield (Greenblatt) % | 0.05 | |||||
| FCF Yield % | -3.44 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BPMC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Blueprint Medicines Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 508.823 | ||
| EPS (TTM) ($) | -1.08 | ||
| Beta | 0.83 | ||
| 3-Year Sharpe Ratio | 0.46 | ||
| 3-Year Sortino Ratio | 0.85 | ||
| Volatility % | 42.65 | ||
| 14-Day RSI | 45.15 | ||
| 14-Day ATR ($) | 3.657382 | ||
| 20-Day SMA ($) | 90.19225 | ||
| 12-1 Month Momentum % | -4.61 | ||
| 52-Week Range ($) | 80.675 - 121.9 | ||
| Shares Outstanding (Mil) | 63.91 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Blueprint Medicines Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Blueprint Medicines Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Blueprint Medicines Corp Frequently Asked Questions
What is Blueprint Medicines Corp(BPMC)'s stock price today?
The current price of BPMC is $89.73. The 52 week high of BPMC is $121.90 and 52 week low is $80.68.
When is next earnings date of Blueprint Medicines Corp(BPMC)?
The next earnings date of Blueprint Medicines Corp(BPMC) is 2025-05-02 Est..
Does Blueprint Medicines Corp(BPMC) pay dividends? If so, how much?
Blueprint Medicines Corp(BPMC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers